Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02508103 · ClinicalTrials.gov registry record · Phase 2

Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study

A Phase 2 study of Premenstrual Dysphoric Disorder, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT02508103 is a Phase 2 study of Premenstrual Dysphoric Disorder that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02508103, a Phase 2 study of Premenstrual Dysphoric Disorder, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This research study will look at brain and symptom differences among women with severe premenstrual mood symptoms. One goal of this study is to look at the effects of taking a nasal spray containing oxytocin (a hormone made in the brain) on brain areas involved in emotion regulation while viewing pictures during a neuroimaging (fMRI) session. The investigators will also look at whether oxytocin improves premenstrual mood symptoms.

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-07
Est. Completion 2016-07
Phase Phase 2

What the Registry Record Tells You About NCT02508103

The ClinicalTrials.gov registry entry for NCT02508103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Premenstrual Dysphoric Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02508103 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02508103 about?

NCT02508103 is a clinical study titled "Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study". This research study will look at brain and symptom differences among women with severe premenstrual mood symptoms. One goal of this study is to look at the effects of taking a nasal spray containing oxytocin (a hormone made in the brain) on brain areas involved in emotion regulation while viewing pi...

What is the current status of trial NCT02508103?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-07. Estimated completion is 2016-07.

What conditions does trial NCT02508103 study?

This clinical trial studies the following conditions: Premenstrual Dysphoric Disorder.

What interventions are being tested in trial NCT02508103?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT02508103?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02508103 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premenstrual Dysphoric Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.